Species level identification and antifungal susceptibility of yeasts isolated from various clinical specimens and evaluation of Integral System yeasts Plus

New Microbiologica

Volumn 35, Issue 3, 2012, Pages 327-334

  Bicmen, Can ^a   Doluca, Mine ^b   Gulat, Sinem ^b   Gunduz, Ayriz T ^a   Tuksavul, Fevziye ^a  

^a Dr Suat Seren Training and Research Hospital for Chest Diseases and Chest Surgery   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Candida; Identification; Integral system; Susceptibility testing; Yeast

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANALYTICAL EQUIPMENT; ARTICLE; CANDIDA; CLASSIFICATION; COLORIMETRY; DRUG EFFECT; EVALUATION; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD;

AMPHOTERICIN B; CANDIDA; COLORIMETRY; DRUG RESISTANCE, MULTIPLE, FUNGAL; FLUCONAZOLE; FLUCYTOSINE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TRIAZOLES;

CANDIDA; CANDIDA PARAPSILOSIS;

EID: 84864537618     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. ARIKAN S., REX J. H. (2009). Fungal drug resistance assays. In: Antimicrobial Drug Resistance: Clinical and Epidemiological Aspects. Mayers DL Ed., New York: Humana Press, a part of Springer Science+Business Media, LLC, pp. 1171-1186.
2. CLARK T. A., HAJJEH R. A. (2002). Recent trends in the epidemiology of invasive mycoses. Curr. Opin. Infect. Dis. 15, 569-574. (Pubitemid 36026968)
3. CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI). (2002). Reference method for broth dilution anti-fungal susceptibility testing of yeasts; Approved Standard NCCLS document M27-A2. Wayne, Pa: CLSI.
4. CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI). (2008a). Reference method for broth dilution anti-fungal susceptibility testing of yeasts: third edition (M27-A3). Wayne, PA: CLSI.
5. CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI). (2008b). Reference method for broth dilution anti-fungal susceptibility testing of yeasts: third informational supplement (M27-S3). Wayne, PA: CLSI.
6. DIEKEMA D. J., MESSER S. A., BOYKEN L. B., HOLLIS R. J., KROEGER J., TENDOLKAR S., PFALLER M. A. (2009). In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth mi-crodilution methods. J. Clin. Microbiol. 47, 3170-3177.
7. DONOGHUE M., SEIBEL N. L., FRANCIS P. S., WALSH T. J. (2009). Fungal infections of the respiratory tract. In: Clinical Mycology. 2nd ed. Anaissie E. J., McGinnis M. R., Pfaller M. A. Eds., Churchill Livingstone Elsevier Inc., pp. 561-591.
8. © for antifungal susceptibility testing of yeasts isolated from blood cultures against four antifungal agents. New Microbiol. 34, 195-201.
9. FREYDIERE A. M., GUINET R., BOIRON P. (2001). Yeast identification in the clinical microbiology laboratory: phenotypical methods. Med. Mycol. 39, 9-33. (Pubitemid 32192914)
10. FLECK R., DIETZ A., HOF H. (2007). In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J. Antimicrob. Chemother. 59, 767-771. (Pubitemid 47073416)
11. FRICKER-HIDALGO H., VANDAPEL O., DUCHESNE M. A., MAZOYER M. A., MONGET D., LARDY B., ET AL. (1996). Comparison of the new API Candida system to the ID 32C system for identification of clinically important yeast species. J. Clin. Microbiol. 34, 1846-1848. (Pubitemid 26190437)
12. KAUFFMAN C. A. (2006). Fungal infections. Proc. Am. Thorac. Soc. 3, 35-40.
13. KENNEDY M. A., SOBEL J. D. (2010). Vulvovaginal can-didiasis caused by non-albicans Candida species: New Insights. Curr. Infect. Dis. Rep. 12, 465-470.
14. KRCMERY V., BARNES A. J. (2002). Non-albicans Candida spp. causing fungaemia: pathogenicity and anti-fungal resistance. J. Hosp. Infect. 50, 243-260. (Pubitemid 37554852)
15. LIGUORI G., GALLÉ F., LUCARIELLO A., ONOFRIO V. D., ALBANO L., MAZZARELLA G., D'AMORA M., ROSSANO F. (2010). Comparison between multiplex PCR and phenotypic systems for Candida spp. identification. New Microbiol. 33, 63-67.
16. LYON G. M., KARATELA S., SUNAY S., ADIRI Y. FOR THE CANDIDA SURVEILLANCE STUDY INVESTIGATORS (2010). Antifungal susceptibility testing of Candida isolates from the Candida Surveillance Study. J. Clin. Microbiol. 48, 1270-1275.
17. MORACE G., AMATO G., BISTONI F., FADDA G., MARONE P., MONTAGNA M. T., ET AL. (2002). Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida Species. J. Clin. Microbiol. 40, 2953-2958. (Pubitemid 35284969)
18. MORACE G., BORGHI E. (2010). Fungal infections in ICU patients: epidemiology and the role of diagnostics. Minerva Anestiologica 76, 950-956.
19. PARK B. J., ARTHINGTON-SKAGGS B. A., HAJJEH R. A., IQBAL N., CIBLAK M. A., LEE-YANG W., ET AL. (2006). Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents. Chemother. 50, 1287-1292.
20. PFALLER M. A., CASTANHEIRA M., MESSER S. A., MOET G. J., JONES R. N. (2010). Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn. Microbiol. Infect. Dis. 68, 278-283.
21. PFALLER M. A., CASTANHEIRA M., MESSER S. A., MOET G. J., JONES R. N. (2011) Echinocandin and triazole anti-fungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumiga-tus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69, 45-50.
22. POSTERARO B., ROMANO L., SANGUINETTI M., MASUCCI L., MORACE G., FADDA G. (2000). Commercial systems for fluconazole susceptibility testing of yeasts: comparison with the broth microdilution method. Diagn. Microbiol. Infect. Dis. 38, 29-36.
23. RODRIGUEZ-TUDELA J. L., ARENDRUP M. C., BARCHIESI F., BILE J., CHRYSSANTHOU E., CUENCA-ESTRELLA M., ET AL. (2008). EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14, 398-405. (Pubitemid 351356536)
24. SINGH S., SOBEL J. D., BHARGAVA P., BOIKOV D., VAZQUEZ J. A. (2002). Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin. Infect. Dis. 35, 1066-1070. (Pubitemid 35239466)
25. SOBEL J. D. (2007). Vulvovaginal candidosis. Lancet 369, 1961-71. (Pubitemid 46874580)
26. TAY S. T., NA S. L., CHONG J. (2009). Molecular differentiation and antifungal susceptibilities of Candida parapsilosis isolated from patients with bloodstream infections. J. Med. Microbiol. 58, 185-191.